No data available.
No data available.
| S.No. | Ticker | Company | Market Cap | P/E | P/S | Total Debt (Qtr) |
|---|---|---|---|---|---|---|
| 1 | SMMT | Summit Therapeutics Inc. | 1,446.17 Bn | -1,569.17 | 0.00 | 0.01 Bn |
| 2 | ONC | BeOne Medicines Ltd. | 439.23 Bn | 6,407.40 | 88.33 | 1.90 Bn |
| 3 | VRTX | Vertex Pharmaceuticals Inc / Ma | 120.62 Bn | 32.82 | 10.29 | 1.83 Bn |
| 4 | REGN | Regeneron Pharmaceuticals, Inc. | 84.40 Bn | 18.44 | 5.92 | 2.71 Bn |
| 5 | ALNY | Alnylam Pharmaceuticals, Inc. | 56.13 Bn | 1,288.39 | 17.49 | 3.21 Bn |
| 6 | ARGX | Argenx Se | 47.89 Bn | 31.79 | 24,973.95 | - |
| 7 | BNTC | Benitec Biopharma Inc. | 42.45 Bn | -1,015.00 | 0.00 | 0.00 Bn |
| 8 | INSM | INSMED Inc | 32.67 Bn | -27.60 | 73.08 | 0.74 Bn |
| Current Valuation | Value | Ind Avg | Percentile |
|---|---|---|---|
| EV to Assets EV to Assets | 18.58 | 12.96 | |
| EV to Cash from Ops. EV/CFO | -26.96 | 23.73 | |
| EV to Debt EV to Debt | 16.38 | 772.65 | |
| EV to EBIT EV/EBIT | -21.61 | -11.30 | |
| EV to EBITDA EV/EBITDA | -19.84 | 7.11 | |
| EV to Free Cash Flow [EV/FCF] EV/FCF | -26.52 | 22.12 | |
| EV to Market Cap EV to Market Cap | 1.04 | 68.89 | |
| EV to Revenue EV/Rev | 82.61 | 199.70 | |
| Price to Book Value [P/B] P/B | -11.66 | 22.62 | |
| Price to Earnings [P/E] P/E | -15.57 | -12.30 |
| Dividend Metrics | Value | Ind Avg | Percentile |
|---|---|---|---|
| Dividend Coverage Ratio Dividend Coverage Ratio | 0.00 | -12.02 | |
| Dividend Payout Ratio % Dividend Payout Ratio % | 0.00 | 0.17 | |
| Dividend per Basic Share Div per Share (Qtr) | 0.00 | 0.01 | |
| FCF Dividend Payout Ratio % FCF Dividend Payout Ratio % | 0.00 | -0.15 | |
| Interest Coverage Interest Coverage | -3.02 | 857.11 |
| Growth Metrics | Value | Ind Avg | Percentile |
|---|---|---|---|
| Capex Growth (1y) % Capex Growth (1y) % | -11.80 | -27.24 | |
| Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) | -52.47 | 747.06 | |
| Dividend Growth (1y) % Dividend Growth (1y) % | 0.00 | 0.01 | |
| EBIAT Growth (1y) % EBIAT Growth (1y) % | -105.54 | -48.21 | |
| EBITDA Growth (1y) % EBITDA Growth (1y) % | -96.91 | -2.09 | |
| EBIT Growth (1y) % EBIT Growth (1y) % | -107.30 | -57.79 | |
| EBT Growth (1y) % EBT Growth (1y) % | -70.25 | -14.35 | |
| EPS Growth (1y) % EPS Growth (1y) % | -61.16 | -30.88 | |
| FCF Growth (1y) % FCF Growth (1y) % | -2,146.53 | -32.51 | |
| Gross Profit Growth (1y) % Gross Profit Growth (1y) % | -73.67 | 227.96 |
| Liquidity Ratios | Value | Ind Avg | Percentile |
|---|---|---|---|
| Asset Utilization Ratio Asset Utilization Ratio | 0.26 | 0.14 | |
| Cash Payout Ratio Cash Payout Ratio | 0.00 | 0.00 | |
| Cash Ratio Cash Ratio (Qtr) | 0.46 | 3.79 | |
| Current Ratio Curr Ratio (Qtr) | 0.63 | 7.23 | |
| Debt to Equity Ratio Debt/Equity (Qtr) | -0.74 | 0.42 | |
| Interest Cover Ratio Interest Cover Ratio | -3.02 | 857.11 | |
| Times Interest Earned Times Interest Earned | -3.02 | 857.11 |
| Profitability | Value | Ind Avg | Percentile |
|---|---|---|---|
| EBITDA Margin % EBITDA Margin % | -366.10 | -18,509.94 | |
| EBIT Margin % EBIT Margin % | -324.87 | -18,862.18 | |
| EBT Margin % EBT Margin % | -508.76 | -19,783.19 | |
| Gross Margin % Gross Margin % | 100.00 | -8.62 | |
| Net Profit Margin % Net Profit Margin % | -508.40 | -19,732.60 |